A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Study Summary

The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Conditions

Thyroid Eye Disease

Interventions / Drugs

AMG 732 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment88 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157629+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.